| INTRODUCTION
Cirrhosis is the end-stage of chronic liver diseases with various aetiologies. On a global scale chronic viral hepatitis is the most common cause of cirrhosis while the second most common cause is excessive alcohol consumption. 1, 2 Evidence suggests that 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, that is, statins have ameliorating effects on the inflammatory processes in cirrhosis. Studies from the laboratory demonstrated that statins inhibit proliferation of hepatic stellate cells and improve sinusoidal endothelial dysfunction in rats. 3, 4 Robust evidence of a beneficial effect of statins in patients with cirrhosis comes from two randomised interventional studies that have shown a significant decrease in hepatic venous pressure gradient. 5, 6 Finally, in a randomised multicentre study of 158 patients with cirrhosis, who had recovered from a bleeding episode, a decrease in mortality was found among the simvastatin treated patients albeit mortality was not the primary endpoint. 7 Clinical retrospective studies have reported an association between use of statins and decreased risk of death and decompensation in patients with cirrhosis due to hepatitis B virus (HBV), 8 hepatitis C virus (HCV) 9 and mixed aetiologies. 10 No population based studies on patients with alcoholic cirrhosis exist that examines the relationship between exposure to statins and mortality.
The aims of this study were to assess the association between use of statins and death and decompensation in a matched analysis.
| ME TH ODS
The cohorts were retrieved from Danish registers from the period 1995 through 2014. The data came from the Danish National
Patient Registry based on International Classification of Diseases, 10th revision (ICD-10), 11 the Danish National Prescription Registry based on Anatomical Therapeutic Chemical (ATC) classification system, 12 the Danish Register of Causes of Death based on ICD-10, 13 and the Danish Civil Registration System. 14 
| Patients
We identified patients using the ICD-10 code for alcoholic cirrhosis 
| Endpoints
Primary endpoint was death and the secondary endpoint was decompensation, which was a composite endpoint that consisted of ascites (R18), paracentesis (Danish Hospitals' Classification System
[SKS] KTJA10), oesophageal varices with bleeding (I85), initiation of spironolactone or furosemide, or banding of varices (SKS code KJCA20/KJCA22).
| Exposure to statins
We distinguished between being in treatment and not in treatment with statins using all prescription claims of statins after the index date and established a prescription claims pattern for each particular patient. Whenever a patient had filled a prescription of statins at least twice, we used the time of the second claim as the beginning of treatment with statins. The total time of statin treatment had to be more than 1 month. For all nonstatin persons in the nonmatched analysis we postponed the cohort entry with 30 days after the index date or excluded the person if death occurred within 30 days after the index date ( Figure S1 ).
We also assessed the pattern of statin claims as a stochastic process based on patients with at least five claims. 
Patients from Danish nationwide registries were included if they had a history of alcoholic cirrhosis. This figure shows how patients with cirrhosis were included in the unmatched and propensity score matched cohort in the analysis of mortality had three consecutive periods with stable dosing of statins they entered a sub-cohort for further analysis ( Figure S2 ).
| Doses and types of statins
We assessed the cumulated defined daily doses of statins relative to follow-up time and whether the claims were for simvastatin We wanted to address healthy adherer effect for patients with cirrhosis. 18 To asses behaviours that correlate with medical adherence we evaluated the claiming pattern of opioids (ATC N02A) as a stochastic process (Data S1). This could be done for all patients with five or more claims of opioids and we clustered the patients into four groups based on the stability in opioids claims. This clusteringor healthy adherence profile-was used as covariate and in the propensity score (PS) matching process.
| Statistics
Demographics were expressed in means with standard deviation, medians with 1st and 3rd quartiles (Q1-Q3), or frequencies and tested for differences using the t test, Fisher's exact test or Kolmogorov-Smirnov test when appropriate. The endpoints, decompensation and mortality, were expressed in rates as events per 1,000
person-years (P-Y) with 95% confidence interval (CI). Differences in rates between the statin and nonstatin group were expressed as hazard-ratios (HR) with 95% CI based on Cox-regression analysis.
We used PS matching based on a greedy algorithm to match each patient using statins with two patients not using statins. Cohort entry for statin users was the initiation of statin treatment according to the above mentioned methods and hence cohort entry was later than the index date. The cohort entry for nonstatin patients was postponed accordingly so it equaled the time from index date to cohort entry of the PS matched statin-user and the nonstatin persons could only enter the PS matched analysis if death had not occurred ( Figure S3 ). End of follow-up was time of the studied endpoint or 31 December 2014. Our primary analysis was the adjusted analysis based on the PS matched cohort of patients with a healthy adherer profile based on opioid claims. However, because this analysis would be based solely on patients receiving opioids, we also report the results based on the PS matched cohort of patients without a healthy adherer profile (Supporting information). A two-sided P-value of .05 was the threshold for statistical significance and we used SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
| Simulation of statistical model
Because retrospective studies are prone to suffer from residual biases 18 we wanted to test our method on a cohort in which the death status (death/alive) and risk time was detached from all biological context. We extracted index date, death status, and end of follow-up from the patient identifier and hence also the covariates.
Then they were sorted randomly based on a random number generator and subsequently they were re-attached to another patient identifier. In this way we kept the distribution of death status and risk time but each patient was assigned with another patient's death status, index date and end of follow-up. We then ran the programs that assessed the exposure to statins. Any significant associations between simulated mortality and exposure to statins would be due to flaws in the statistical model or by chance. We did three separate mortality analyses based on simulated mortality: (1) using the unmatched cohort, (2) using the PS matched cohort without matching according to time from diagnosis of cirrhosis and finally, (3) an analysis on the PS matched cohort with time matching as well as described above.
| RESULTS
A total of 24 748 patients were identified with cirrhosis during the study period. We excluded 1763 cases with cancer, 584 cases with chronic viral hepatitis C, 277 cases with non-alcoholic fatty liver disease, and 3019 patients were excluded due to a follow-up time of less than one month. Of the remaining 19 105 patients with cirrhosis (Table S1 ) we could determine a healthy adherer profile based on opioid claims for 5417 patients. Eventually 744 patients of these 5417 patients were matched based on PS (Table 1) .
For the endpoint decompensation, we excluded 1763 patients due to cancer, 584 due to chronic viral hepatitis, 277 patients due to non-alcoholic fatty liver disease and 10 605 because the endpoint decompensation occurred less than 30 days after cohort entry. Ultimately 3582 patients with a healthy adherer profile entered the analysis of decompensation as endpoint of which 375 entered the PS matched analysis.
| The endpoints and statins
In the unmatched cohort of 5417 patients a total of 794 (15%) had redeemed statins at least twice with a minimum span of 30 days between first and last statin claim. The greatest difference in baseline characteristics was in terms of use of diuretics, beta-blockers, alcohol intoxication, and the presence of an indication for therapy with statins. The PS matching process did reduce the differences in baseline characteristics that, however, remained statistically different for some covariates (Table 1 ).
In the unmatched cohort we found mortality rates of 96 (86- Table 3 .
For the endpoint decompensation we found the rate of decom- The table shows the rates of the studied endpoints-mortality and decompensation-among patients with alcoholic cirrhosis and a healthy adherer profile based on claims of opioids. The patients are stratified into users of statins and non-users and the difference in mortality is expressed in hazard ratio with 95% CI. | 677 of gliding averages of 13 (6-24) per patient and median statin dose of 2.6 (95% CI 1.2-9.5) DDD for each patient. Each increment in statin dose of one DDD was associated with a slightly increased risk of death with a HR of 1.04 (1.03-1.05; P<.0001). We evaluated the medical adherence by the frequency of periods that were determined as being "stable" for each statin user and the overall median likelihood of being in a stable state was 54% (31%-77%) for 564 patients with cirrhosis. The patients were clustered into four groups based on each patient's likelihood of being in a stable period and mortality was assessed with reference to the group of patients with the best adherence (i.e. highest frequency of stable periods). The patients with the lowest likelihood of being in a stable state had an increased risk of death compared with the patients with a higher likelihood ( Figure 3 and Table 4 ). For each increase of 25% in likelihood of being in a stable state regarding dose of statins we found a reduced risk of death of 16% (95% CI 5%-26%). Regarding types of statins, we found the most frequently prescribed statin to be simvastatin that was used by 79% of the patients followed by atorvastatin by 8% of the patients, and 7% with simvastatin and atorvastatin.
The remaining 6% of the patients were prescribed with rosuvastatin alone or alternating with simvastatin or atorvastatin.
| Model simulation
In this model we included 4362 patients with a healthy adherer pro- Patients with at least five claims of statins were clustered into groups depending on the likelihood of being on a stable dose of statins compared with the previous period. All claims of statins for these patients were evaluated and the group of patients who were most likely to be in a stable period was used for reference in the analysis of mortality ( Figure S2 ).
a HR-adjusted for number of statin claims as well as the other covariates. increment in DDD of statins when we used the moving average approach. We also found a lower mortality among patients with a higher likelihood of being in a period of stable statin dosing, which suggests that a constant in contrast to a changing exposure to statins has an effect on survival. Among the 794 patients who had redeemed statins twice, we found 387 (49%) patients with three consecutive stable periods of statin claims and these patients had an increased survival compared with nonstatin patients.
Our results may be hampered by residual bias of several types, that is, healthy user bias, healthy adherer bias, and confounding by selective prescribing, all of which may lead to an over estimation of the association between statins and the endpoint. Healthy user bias is usually accounted for by PS matching that, however, may suffer from insufficient number of covariates. In our study there was lack of medical history and biochemical data that would have permitted a clinical staging at baseline. Based on earlier reports we suspect that patients in treatment with statins have less severe cirrhosis, which could contribute to the observed association between statins and mortality. 9 We addressed healthy user bias using the prescription pattern of opioids. The strength of this study is our analysis of exposure to statins as a stochastic process, which allows for an evaluation of medical adherence and a time dependent exposure to different doses of statins. With this method we found an association between mortality and the constancy by which statins were claimed by the patients.
Our results are in concordance with earlier retrospective studies of patients with cirrhosis due to chronic HBV or HCV infection with regard to the association between statin use and mortality and decompensation, 8, 9 In the study by Huang et al. 8 a dose-response association was reported but the results were severely hampered by immortal time bias. 19 Nevertheless, none of the previously published retrospective studies matched the patients using time from diagnosis to initiation of statins. A possible mechanism behind the observed relationship between use of statins and mortality may be due to a lower risk of infections. 20 We conclude that the use of statins was associated with a reduced risk of decompensation and death in patients with alcoholic cirrhosis and the association between use of statins and death was more pronounced in patients with cirrhosis compared with noncirrhotic controls. No convincing dose-response association was found but patients with a more constant exposure to statins may benefit more from the treatment. Nevertheless, the results need to be verified in controlled clinical trials before statins can be recommended for patients with alcoholic cirrhosis.
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